Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07224334Phase 1Recruiting

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

Role: lead

NCT02550548Phase 1Completed

Incretin Action in Physiology and Diabetes

Role: lead

NCT04347252Phase 1Completed

Glucagon Regulation of Glucose Metabolism

Role: lead

NCT02683187Phase 1Completed

DPP4 Inhibition & Beta Cell Function

Role: lead

All 4 trials loaded